lncRNA SNHG26 promoted the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through PGK1/Akt/mTOR signal pathway

Jiang, Qingkun; Wang, Zhonghao; Qi, Qi; Li, Jialun; Yong, Xin; Qiu, Jiaxuan

doi:10.1016/j.omto.2021.12.021

Cited by 19 publications

(16 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lang et al found that the lncRNA PCAT6 could enhance IGF1R mRNA stability through the PCAT6/IGF2BP2/IGF1R RNA-protein complex, which was induced in an m6A manner (23). In tongue squamous cancer, Jiang et al noticed that the lncRNA SNHG26 could enhance cell malignant biological behaviors and cisplatin resistance of cancer by affecting the PGK1/Akt/mTOR signaling (24). Our result indicated these m6A-related lncRNAs in colon cancer, which can improve the understanding of their action model and provide direction for future studies.…”

Section: Discussionsupporting

confidence: 55%

The comprehensive analysis identifies the lncRNA involved in N6- methyladenosine and glycolysis activity in colon cancer

Luo

Xie

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: N6-methyladenosine (m6A) exerted an important role in colon cancer. Nevertheless, the lncRNAs involved in this process remain unclear. Methods: The open-accessed data used for analysis was downloaded from The Cancer Genome Atlas (TCGA) database and analyzed using the R software. Results: In our study, we firstly collected the expression value of m6A regulators from TCGA data. Then, the lncRNAs with |Cor| > 0.3 and P < 0.05 of these m6A molecules were identified and defined as m6A-related lncRNAs. Moreover, we established a prognosis signature based on ten m6A-related lncRNAs, consisting of AL360181.1, PCAT6, SNHG26, AC016876.1, AC104667.2, AL114730.3, LINC02257, AC147067.1, AP006621.3 and AC009237.14, which showed satisfactory prediction efficiency in patients survival. Immune-related analysis indicated a diverse immune cell infiltration pattern between high and low risk patients. Also, we found that the low risk patients might be more sensitive to immunotherapy. Biological enrichment analysis indicated that the high risk patients had a higher activity of multiple carcinogenic pathways, including glycolysis. The lncRNA AL360181.1 has not been reported previously. Meanwhile, the lncRNA AL360181.1 was correlated with glycolysis activity and worse survival performance, therefore selected for further analysis. The result indicated that AL360181.1 was correlated with worse clinical features. Immune infiltration analysis indicated that AL360181.1 was positively correlated with Tcm infiltration, yet negatively correlated with Th2 cells, T cells, neutrophils, iDC and macrophages. Biological enrichment analysis indicated that the pathways of WNT/β-catenin, pancreas beta cells, hedgehog signaling, bile acid metabolism, bile acid metabolism, and fatty acid metabolism were upregulated in the patients with high AL360181.1 expression Conclusions: Our result can improve the understanding of m6A-related lncRNA in colon cancer and provide direction for future studies.

show abstract

Section: Discussionsupporting

confidence: 55%

The comprehensive analysis identifies the lncRNA involved in N6- methyladenosine and glycolysis activity in colon cancer

Luo

Xie

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Of note, some investigations have shown that PGK1 activates the AKT/mTOR signaling pathway in non-small cell lung cancer and tongue squamous cell carcinoma. [20,21] In this research, we also noted that knocking down PGK1 lessened the phosphorylation level of S6K1 T389 in MNNG/HOS and U-2OS cells (Figure 3A). Using the co-IP assay, we found that PGK1 interacted with PD-L1 or NPM PD-L1 in osteosarcoma cells (Figure 3B).…”

Section: Hyperphosphorylated Pd-l1 Enhances the Interaction Between P...supporting

confidence: 61%

Targeted Delivery of PD‐L1‐Derived Phosphorylation‐Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment

Guo

Jing

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Osteosarcoma is a rare malignant bone-originating tumor that usually occurs in young people. Programmed cell death 1 ligand 1 (PD-L1), an immune checkpoint protein, is highly expressed in osteosarcoma tissues. Several recent studies have indicated that the tumor-related role of PD-L1 in tumors, especially non-plasma membrane (NPM)-localized PD-L1, is not limited to immune regulation in osteosarcoma. Here, mass spectrometry analysis is combined with RNA-seq examination to identify the intracellular binding partners of PD-L1 and elucidate the underlying mechanism of its action. It is found that the NPM-localized PD-L1 interacted with Insulin-like growth factor binding protein-3 (IGFBP3) to promote osteosarcoma tumor growth by activating mTOR signaling. This interaction is enforced after phosphoglyceratekinase1 (PGK1)-mediated PD-L1 phosphorylation. Based on these findings, a phosphorylation-mimicking peptide is designed from PD-L1 and it is encapsulated with a Cyclic RGD (cRGD)-modified red blood cell membrane (RBCM) vesicle

show abstract

“…Similarly, a four-lncRNA signature that included SNHG26 was associated with immune infiltration and prognosis in colon cancer; the signature-divided colon cancer patients of TCGA into high- and low-risk groups with significantly different outcomes ( 208 ). In TSCC, SNHG26 expression was positively correlated with proliferation, EMT, migration, invasion, and cisplatin resistance by activating the AKT/mTOR signaling pathway ( 104 ).…”

Section: Lncrnas In Drug Resistance Mechanismsmentioning

confidence: 99%

“…Lin et al proposed CILA1 as a biomarker in TSCC, correlating its expression levels with cisplatin resistance and advanced disease stage (110). Moreover, SNHG26 expression was also associated with the occurrence, progression, and poor prognosis of TSCC (104).…”

Section: Clinical Relevance Of Lncrnas In Drug Resistance Mechanisms ...mentioning

confidence: 99%

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma

et al. 2022

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) originates in the squamous cell lining the mucosal surfaces of the head and neck region, including the oral cavity, nasopharynx, tonsils, oropharynx, larynx, and hypopharynx. The heterogeneity, anatomical, and functional characteristics of the patient make the HNSCC a complex and difficult-to-treat disease, leading to a poor survival rate and a decreased quality of life due to the loss of important physiologic functions and aggressive surgical injury. Alteration of driver-oncogenic and tumor-suppressing lncRNAs has recently been recently in HNSCC to obtain possible biomarkers for diagnostic, prognostic, and therapeutic approaches. This review provides current knowledge about the implication of lncRNAs in drug resistance mechanisms in HNSCC. Chemotherapy resistance is a major therapeutic challenge in HNSCC in which lncRNAs are implicated. Lately, it has been shown that lncRNAs involved in autophagy induced by chemotherapy and epithelial–mesenchymal transition (EMT) can act as mechanisms of resistance to anticancer drugs. Conversely, lncRNAs involved in mesenchymal–epithelial transition (MET) are related to chemosensitivity and inhibition of invasiveness of drug-resistant cells. In this regard, long non-coding RNAs (lncRNAs) play a pivotal role in both processes and are important for cancer detection, progression, diagnosis, therapy response, and prognostic values. As the involvement of more lncRNAs is elucidated in chemoresistance mechanisms, an improvement in diagnostic and prognostic tools could promote an advance in targeted and specific therapies in precision oncology.

show abstract

lncRNA SNHG26 promoted the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through PGK1/Akt/mTOR signal pathway

Cited by 19 publications

References 55 publications

The comprehensive analysis identifies the lncRNA involved in N6- methyladenosine and glycolysis activity in colon cancer

The comprehensive analysis identifies the lncRNA involved in N6- methyladenosine and glycolysis activity in colon cancer

Targeted Delivery of PD‐L1‐Derived Phosphorylation‐Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment

Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About